Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects With Ankylosing Spondylitis

NCT01248793 is registered in ClinicalTrials.gov with Centocor, Inc. as lead sponsor.

NCT NCT01248793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01248793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects With Ankylosing Spondylitis
Lead sponsor
Centocor, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2010
Completion date
March 31, 2012
Enrollment
213 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis